Earnings ·
Neumora Therapeutics reported second quarter 2026 financial results and announced a leadership transition effective…
NMRANeumora Therapeutics, Inc.
Neumora Therapeutics reported second quarter 2026 financial results and announced a leadership transition effective August 14, 2026. Joshua Pinto, Ph.D., succeeded Paul L. Berns as Chief Executive Officer and was appointed to the Board of Directors; Mr. Berns became Executive Chairperson. Doron Sagman, M.D., FRCPC, was appointed Chief Medical Officer. For the quarter ended June 30, 2026, the company reported a net loss of $43.1 million, compared to $52.7 million in the prior year period. Research and development expenses decreased to $29.3 million from $38.7 million, while general and administrative expenses fell to $12.9 million from $15.3 million. The company held $116.8 million in cash and cash equivalents as of June 30, 2026, which is expected to fund operations into the third quarter of 2027. Neumora Therapeutics operates in the biopharmaceutical industry, developing clinical-stage treatments for brain diseases.